GLP-1-receptoragonisten en renoprotectie in type 2-diabetes
Marcel H.A. Muskiet(Amsterdam University Medical Centers), Ellen M. Apperloo(Dialyse Centrum Groningen)
Cited by 0
Related Papers
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
|The Lancet Diabetes & Endocrinology|2024|135
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
|Nature Medicine|2024|95
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
|Diabetes Care|2023|89
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials
|Diabetes Care|2025|42
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
|Diabetes Obesity and Metabolism|2023|28